Inhibition of Poly(ADP-Ribose) Polymerase Modulates Tumor-Related Gene Expression, Including Hypoxia-Inducible Factor-1 Activation, during Skin Carcinogenesis
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Poly(ADP-ribose) polymerase (PARP)-1, an enzyme that catalyzes the attachment of ADP ribose to target proteins, acts as a component of enhancer/promoter regulatory complexes. In the present study, we show that pharmacologic inhibition of PARP-1 with 3,4-dihydro-5-[4-(1-piperidinyl)butoxyl]-1(2H)-isoquinolinone (DPQ) results in a strong delay in tumor formation and in a dramatic reduction in tumor size and multiplicity during 7,12-dimethylbenz(a)anthracene plus 12-O-tetradecanoylphorbol-13-acetate–induced skin carcinogenesis. This observation was parallel with a reduction in the skin inflammatory infiltrate in DPQ-treated mice and tumor vasculogenesis. Inhibition of PARP also affected activator protein-1 (AP-1) activation but not nuclear factor-κB (NF-κB). Using cDNA expression array analysis, a substantial difference in key tumor-related gene expression was found between chemically induced mice treated or not with PARP inhibitor and also between wild-type and parp-1 knockout mice. Most important differences were found in gene expression for Nfkbiz, S100a9, Hif-1α, and other genes involved in carcinogenesis and inflammation. These results were corroborated by real-time PCR. Moreover, the transcriptional activity of hypoxia-inducible factor-1α (HIF-1α) was compromised by PARP inhibition or in PARP-1–deficient cells, as measured by gene reporter assays and the expression of key target genes for HIF-1α. Tumor vasculature was also strongly inhibited in PARP-1–deficient mice and by DPQ. In summary, this study shows that inhibition of PARP on itself is able to control tumor growth, and PARP inhibition or genetic deletion of PARP-1 prevents from tumor promotion through their ability to cooperate with the activation AP-1, NF-κB, and HIF-1α. (Cancer Res 2006; 66(11): 5744-56)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683 · cited 1×
“More recently, two different groups provided strong evidences in the sense that monotherapy with PARP inhibitors was effective in eliminating BRCA-1 and BRCA-2 cancer cells and tumors due to the inability of these cells to repair by homologous recombination the stalled replication fork damages induced by PARP inhibito…”
BackgroundSpecific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
Activators and target genes of Rel/NF-κB transcription factors
Pahl, H. L. (1999) · Oncogene · doi:10.1038/sj.onc.1203239 · Cited by 3,727
Calabrese, C. R., Almassy, R., Barton, S., Batey, M. A., Calvert, A. H., Canan-Koch, S., Durkacz, B. W., Hostomsky, Z., Kumpf, R. A., Kyle, S., et al. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh005 · Cited by 487 · cited 2×
“New highly potent PARP inhibitors have shown their specificity and in vivo activity to enhance chemotherapy and radiotherapy of human cancer (40).”
BackgroundIdentification of a hypoxia response element in the transferrin receptor gene
Lok, C. N., & Ponka, P. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.34.24147 · Cited by 380 · cited 1×
“Gel shift assays were used to detect NF-nB, AP-1, and HIF-1a–binding activity as that by Martin-Oliva et al. (6) and Lok et al. ( 7 ).”
MethodAP1/ jun Function Is Differentially Induced in Promotion-Sensitive and Resistant JB6 Cells
Bernstein, L. R., & Colburn, N. H. (1989) · Science · doi:10.1126/science.2541502 · Cited by 207 · cited 1×
“Thus, the observation that targeting AP-1 and NF-nB elevation prevents tumor promotion and progression has been extended from the mouse JB6 model to mouse and human keratinocyte progression models (15).”
Background
Cited by
Ying, W. (2008) · Antioxidants & Redox Signaling · doi:10.1089/ars.2007.1672 · Cited by 1,494
“Cumulative evidence has indicated increasingly extensive and important roles of PARP-1-mediated gene expression in various biological and pathological processes, such as inflammation and carcinogenesis (8, 111, 118, 141, 187).”
Current Development of Clinical Inhibitors of Poly(ADP-Ribose) Polymerase in Oncology
Ratnam, K., & Low, J. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2260 · Cited by 286
Beyond DNA Repair: Additional Functions of PARP-1 in Cancer
Weaver, A. N., & Yang, E. S. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00290 · Cited by 246
Robust shifts in S100a9 expression with aging: A novel mechanism for chronic inflammation
Swindell, W. R., Johnston, A., Xing, X., Little, A., Robichaud, P., Voorhees, J. J., Fisher, G., & Gudjonsson, J. E. (2013) · Scientific Reports · doi:10.1038/srep01215 · Cited by 124
Nicotinamide for photoprotection and skin cancer chemoprevention: A review of efficacy and safety
Snaidr, V. A., Damian, D. L., & Halliday, G. M. (2019) · Experimental Dermatology · doi:10.1111/exd.13819 · Cited by 121
Metadata
- Authors
- Martin-Oliva, D., Aguilar-Quesada, R., O'Valle, F., Muñoz-Gámez, J. A., Martínez-Romero, R., García del Moral, R., Ruiz de Almodóvar, J. M., Villuendas, R., Piris, M. A., & Oliver, F. J.
- Venue
- Cancer Research
- Published
- 2006-06-01
- Volume
- 66
- Issue
- 11
- Pages
- 5744-5756
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W1998862888
- Cited by
- 138
- References
- 6
- FWCI
- 3.88
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inhibition of Poly(ADP-Ribose) Polymerase Modulates Tumor-Related Gene Expression, Including Hypoxia-Inducible Factor-1 Activation, during Skin Carcinogenesis. https://app.cochat.ai/papers/10.1158/0008-5472.can-05-3050
- The paper
- Martin-Oliva, D., Aguilar-Quesada, R., O'Valle, F., Muñoz-Gámez, J. A., Martínez-Romero, R., García del Moral, R., Ruiz de Almodóvar, J. M., Villuendas, R., Piris, M. A., & Oliver, F. J. (2006). Inhibition of Poly(ADP-Ribose) Polymerase Modulates Tumor-Related Gene Expression, Including Hypoxia-Inducible Factor-1 Activation, during Skin Carcinogenesis. Cancer Research. https://doi.org/10.1158/0008-5472.can-05-3050
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.